All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How do I manage the risk of infection in patients treated with immunotherapies?

Featured
Feb 18, 2021
Share:

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Joshua Hill, Fred Hutchinson Cancer Research Center, Seattle, US. We asked, How do I manage the risk of infection in patients treated with immunotherapies?

As Joshua Hill discusses this subject, he touches on a number of topics including the use of intravenous or subcutaneous immunoglobulins, and when to vaccinate these patients against COVID-19.


Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox